Pfizer's longstanding dominance of the pneumococcal vaccines category could be threatened by Merck & Co, which has just reported new data on its V116 shot in older adu
Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer, and while the latter is comfortably in front at the moment with its Prevnar franchise, Merck has